Studi kasus tentang asuhan keperawatan pada Ny. B.L.U dengan Hipertensi di Puskesmas Alak Kota Kupang

Latar Belakang Hipertensi adalah keadaan di mana tekanan darah mengalami peningkatan yang memberikan gejala berlanjut pada suatu organ target di tubuh. Dalam keluarga jika ada anggota keluarga yang menderita hipertensi dan tidak menjalankan kelima fungsi keluarga tersebut dengan baik hal ini dapat menimbulkan kerusakan yang lebih berat, misalnya stroke (terjadi pada otak dan menyebabkan kematian yang cukup tinggi), penyakit jantung koroner (terjadi kerusakan pembuluh darah jantung), dan hipertrofi ventrikel kiri (terjadi pada otot jantung). Tujuan Mempelajari Asuhan keperawatan dengan pendekatan proses keperawatan pada Ny. B.L.U yang mengalami hipertensi. Metode : Jenis penulisan ini adalah penulisan secara kualitatif, dengan pendekatan studi kasus, sedangkan rancangannya adalah rancangan deskriptif Studi Kasus Keperawatan pada Ny.B.L.U Dengan Hipertensi di Puskesmas Alak Kota Kupang. Hasil : Masalah keperawatan yang didapatkan pada Ny. B.L.U adalah nyeri akut berhubungan dengan proses penyakit, kurang pengetahuan berhubungan dengan kurang terpapar informasi, yang dirawat selama 1 hari dengan melakukan teknik relaksasi, nafas dalam untuk mengatasi rasa nyeri dan memberikan pendidikan kesehatan tentang penyakit hipertensi untuk masalah kurang pengetahuan berhubungan dengan kurang terpapar informasi dan masalah belum teratasi. Kesimpulan : Masalah yang ditemukan, nyeri akut harus ditindak lanjut di oleh perawat yang ada di Puskesmas Alak Kota Kupang agar masalah tersebut dapat teratasi

Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy

Hypertensive patients unable to reach blood pressure (BP) targets with antihypertensive monotherapy may be switched to a combination of two medications with complementary modes of action for improved treatment response. This post hoc analysis pools data from 2812 patients, 1891 of whom were not at goal (diastolic BP [DBP] <90 mm Hg) with amlodipine 5 mg (A5) monotherapy who subsequently switched to telmisartan 40 or 80 mg (T80)/A5 single-pill combination (SPC) or amlodipine 10 mg (A10) monotherapy, and considers an additional 921 patients, 616 of whom were not at goal with A10 monotherapy who switched to telmisartan/amlodipine SPC. Patients switched to telmisartan/amlodipine SPC achieved significantly greater BP reductions compared with continued monotherapy (P<0.0001) with reductions of −15.2/−10.9 mm Hg seen with T80/A5 after 8 weeks in patients switched from A5. BP goal (<140/90 mm Hg), systolic BP goal (<140 mm Hg), and DBP goal (<90 mm Hg) were reached by significantly more patients with telmisartan/amlodipine than with monotherapy (P<0.0001 for all comparisons; 56.1%, 69.7%, and 66.9%, resp., in patients who switched from A5 to T80/A5). Early use of such combination therapy should be considered to quickly reach BP targets, particularly in patients with added risk

HYPOCARNITINAEMIA IN DISORDERS OF ORGANIC ACID METABOLISM

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/23891/1/0000130.pd

Reduction of late stillbirth with the introduction of fetal movement information and guidelines – a clinical quality improvement

We have performed a full cross-validation of this clinical Femina data collection against the routinely collected data of the Medical Birth Registry of Norway to validate the estimates of reduced mortality in the total population. The original estimate of fewer deaths during the intervention with OR 0.7 remains virtually unchanged for the original data collection

24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension

To determine the effectiveness and safety of once-daily combination therapy with amlodipine, valsartan and hydrochlorothiazide for reducing ambulatory blood pressure (ABP) in patients with moderate to severe hypertension, a multicenter, double-blind study was performed (N=2271) that included ABP monitoring in a 283-patient subset. After a single-blind, placebo run-in period, patients were randomized to receive amlodipine/valsartan/hydrochlorothiazide (10/320/25 mg), valsartan/hydrochlorothiazide (320/25 mg), amlodipine/valsartan (10/320 mg) or amlodipine/hydrochlorothiazide (10/25 mg) each morning for 8 weeks. Efficacy assessments included change from baseline in 24-h, daytime and night time mean ambulatory systolic BP (SBP) and diastolic BP (DBP). Statistically significant and clinically relevant reductions from baseline in all these parameters occurred in all treatment groups (P<0.0001, all comparisons versus baseline). At week 8, least squares mean reductions from baseline in 24-h, daytime and night time mean ambulatory SBP/DBP were 30.3/19.7, 31.2/20.5 and 28.0/17.8 mm Hg, respectively, with amlodipine/valsartan/hydrochlorothiazide; corresponding reductions with dual therapies ranged from 18.8–24.1/11.7–15.5, 19.0–25.1/12.0–16.0 and 18.3–22.6/11.1–14.3 mm Hg (P⩽0.01, all comparisons of triple versus dual therapy). Treatment with amlodipine/valsartan/hydrochlorothiazide maintained full 24-h effectiveness, including during the morning hours; all hourly mean ambulatory SBP and mean ambulatory DBP measurements were ⩽130/85 mm Hg at end point. Amlodipine/valsartan/hydrochlorothiazide combination therapy was well tolerated. Once-daily treatment with amlodipine/valsartan/hydrochlorothiazide (10/320/25 mg) reduces ABP to a significantly greater extent than component-based dual therapy and maintains its effectiveness over the entire 24-h dosing period

Computerised interpretation of the fetal heart rate during labour: a randomised controlled trial (INFANT)

Background Continuous electronic fetal monitoring (EFM) in labour is widely used and computerised interpretation has the potential to increase its utility. Objectives This trial aimed to find out whether or not the addition of decision support software to assist in the interpretation of the cardiotocograph (CTG) reduced the number of poor neonatal outcomes, and whether or not it was cost-effective. Design Two-arm individually randomised controlled trial. The allocations were computer generated using stratified block randomisation employing variable block sizes. The trial was not masked. Setting Labour wards in England, Scotland and the Republic of Ireland. Participants Women in labour having EFM, with a singleton or twin pregnancy, at ≥ 35 weeks’ gestation. Interventions Decision support or no decision support. Main outcome measures The primary outcomes were (1) a composite of poor neonatal outcome {intrapartum stillbirth or early neonatal death (excluding lethal congenital anomalies), or neonatal morbidity [defined as neonatal encephalopathy (NNE)], or admission to a neonatal unit within 48 hours for ≥ 48 hours (with evidence of feeding difficulties, respiratory illness or NNE when there was evidence of compromise at birth)}; and (2) developmental assessment at the age of 2 years in a subset of surviving children. Results Between 6 January 2010 and 31 August 2013, 47,062 women were randomised and 46,042 were included in the primary analysis (22,987 in the decision support group and 23,055 in the no decision support group). The short-term primary outcome event rate was higher than anticipated. There was no evidence of a difference in the incidence of poor neonatal outcome between the groups: 0.7% (n = 172) of babies in the decision support group compared with 0.7% (n = 171) of babies in the no decision support group [adjusted risk ratio 1.01, 95% confidence interval (CI) 0.82 to 1.25]. There was no evidence of a difference in the long-term primary outcome of the Parent Report of Children’s Abilities-Revised with a mean score of 98.0 points [standard deviation (SD) 33.8 points] in the decision support group and 97.2 points (SD 33.4 points) in the no decision support group (mean difference 0.63 points, 95% CI –0.98 to 2.25 points). No evidence of a difference was found for health resource use and total costs. There was evidence that decision support did change practice (with increased fetal blood sampling and a lower rate of repeated alerts). Limitations Staff in the control group may learn from exposure to the decision support arm of the trial, resulting in improved outcomes in the control arm. This was identified in the planning stage and felt to be unlikely to have a significant effect on the results. As this was a pragmatic trial, the response to CTG alerts was left to the attending clinicians. Conclusions This trial does not support the hypothesis that the use of computerised interpretation of the CTG in women who have EFM in labour improves the clinical outcomes for mothers or babies